Epidemiology of lower respiratory tract infections in adults

Expert Review of Respiratory Medicine

Volumn 13, Issue 1, 2019, Pages 63-77

  Feldman, Charles ^a   Shaddock, Erica ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Acute exacerbations of chronic obstructive pulmonary disease; community acquired pneumonia; influenza

Indexed keywords

ADULT; ANTIBIOTIC RESISTANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE BURDEN; HUMAN; INCIDENCE; INFECTION RISK; INFECTIOUS AGENT; INFLUENZA; LOWER RESPIRATORY TRACT INFECTION; MORTALITY; NONHUMAN; PNEUMOCOCCAL INFECTION; REVIEW; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VIRUS; AGED; BRONCHIOLITIS; BRONCHITIS; MIDDLE AGED; PNEUMONIA; RESPIRATORY TRACT INFECTION; SMOKING; YOUNG ADULT;

PNEUMOCOCCUS VACCINE;

ADULT; AGED; BRONCHIOLITIS; BRONCHITIS; HUMANS; INFLUENZA, HUMAN; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA; RESPIRATORY TRACT INFECTIONS; SMOKING; YOUNG ADULT;

EID: 85059693673     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2019.1555040     Document Type: Review

References (163)

1. GBD 2015 LRI Collaborators. Estimates of the global, regional and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the global burden of disease study 2015. Lancet Infect Dis. 2017;17:1133–1161
2. Chapter 18. Acute lower respiratory infections. ERS white book. p. 210–223. [cited 2018 Feb20]. Available from: https://www.erswhitebook.org/files/public/Chapters/18_ALRIs.pdf
3. Greene G, Hood K, Little P, et al. Towards clinical definitions of lower respiratory tract infection (LRTI) for research and primary care practice in Europe: an international consensus study. Prim Care Respir J. 2011;20(3):299–306
4. Welte T, Torres A, Nathwani D., Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–79
5. File TM, Marrie TJ., Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130–141
6. Isturiz RE, Luna CM, Ramirez J. Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis. 2010;14:e852–e856
7. Song J-H, Thamlikitkul V, Hsueh P-R. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011;38:108–117
8. Hayes BH, Haberling DL, Kennedy JL, et al. Burden of pneumonia-associated hospitalizations. United States, 2001–2014. Chest. 2018;153(2):427–437
9. Brown JD, Harnett J, Chambers R, et al. The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. BMC Geriatr. 2018;18(1):92
10. Torres A, Cillóniz C, Blasi F, et al. Burden of pneumococcal community-acquired pneumonia in adults across Europe: a literature review. Respir Med. 2018;137:6–13
11. Quan TP, Fawcett NJ, Wrightson JM, et al. Increasing burden of community-acquired pneumonia leading to hospitalization, 1998–2014. Thorax. 2016;21(6):535–542
12. Bertsias A, Tsiligianni IG, Duijker G, et al. Studying the burden of community-acquired pneumonia in adults aged ≥ 50 years in primary health care; an observational study in rural Crete, Greece. Prim Care Respir Med. 2014;24:14017
13. Vissink CE, Huijts SM, de Wit GA, et al. Hospitalization costs for community-acquired pneumonia in Dutch elderly: an observational study. BMC Infect Dis. 2016;16:466
14. Kosar F, Alici DE, Hacibedel B, et al. Burden of community-acquired pneumonia in adults over 18 y of age. Hum Vaccin Immunother. 2017;13(7):1673–1680
15. Tumanan-Mendoza BA, Mendoza VL, Punzalan FER, et al. Economic burden of community-acquired pneumonia among adults in the Philippines: its equity and policy implications in the case rate payments of the Philippine health insurance corporation. Value Health Reg Issues. 2015;6C:118–125
16. Lee JY, Yoo CG, Kim H-J, et al. Disease burden of pneumonia in Korean adults aged over 50 years stratified by age and underlying disease. Korean J Intern Med. 2014;29:773
17. Konomura K, Nagai H, Akazawa M. Economic burden of community-acquired pneumonia among elderly patients: a Japanese perspective. Pneumonia (Nathan). 2017;9:19
18. Ishifuji T, Sando E, Kaneko N, et al. Recurrent pneumonia among Japanese adults: disease burden and risk factors. BMC Pulm Med. 2017;17:12
19. McNeil SA, Qizilbash N, Ye J, et al. A retrospective study of the clinical burden of hospitalized all-cause and pneumococcal pneumonia in Canada. Can Respir J. 2016;2016:ID3605834
20. Chalmers JD, Campling J, Dicker A, et al. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med. 2016;16:77
21. Earle K, Williams S. Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective. Pneumonia. 2016;8:9
22. Broulette J, Yu H, Pyenson B, et al. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits. 2013;6(8):494–503
23. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. Adults N Engl J Med. 2015;373(5):415–427
24. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–1812
25. Millett ERC, Quint JK, Smeeth L, et al. Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. PLoS ONE. 2013;8(9):e75131
26. Chalmers J, Campling J, Ellsbury G, et al. Community-acquired pneumonia in the United Kingdom: a call to action. Pneumonia (Nathan). 2017;9:15
27. Rivero-Calle I, Pardo-Seco J, Aldaz P, et al. Incidence and risk factor prevalence of community-acquired pneumonia in adults in primary care in Spain (NEUMO-ES-RISK project). BMC Infect Dis. 2016;16:645
28. Bjarnason A, Westin J, Lindh M, et al. Incidence, etiology, and outcomes of community-acquired pneumonia: a population-based study. Open Forum Infect Dis. 2018;5(2):ofy010
29. Partouche H, Lepoutre A, Buffel Du Vaure C, et al. Incidence of all-cause adult community-acquired pneumonia in primary care settings in France. Mel Mad Infect. 2018;48(6):389-395
30. Azmi S, Aljunid SM, Maimaiti N, et al. Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines. Int J Infect Dis. 2016;49:87–93
31. Rozenbaum MH, Mangen MJ, Huijts SM, et al. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis. Vaccine. 2015;33:3193–3199
32. Tang X, Zhu Y, Lu Y, et al. Contemporary situation of community-acquired pneumonia in China: a systematic review. Am J Respir Crit Care Med. 2017;195:A6866
33. Sharma S, Sneath E, Cheng AC, et al. Community-acquired syndromes causing morbidity and mortality in Australia. Commun Dis Intell Q Rep. 2017;41(1):E49–E57
34. Lopardo GD, Fridman D, Raimondo E, et al. Incidence rate of community-acquired pneumonia in adults: a population-based prospective active surveillance study in three cities in South America. BMJ Open. 2018;8(4):019439
35. Choi MJ, Song JY, Noh JY, et al. Disease burden of hospitalized community-acquired pneumonia in South Korea: analysis based on age and underlying medical conditions. Medicine (Baltimore). 2017;96(44):e8429
36. Heo JY, Seo YB, Choi WS, et al. Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: catchment population-based analysis. PLoS One. 2018;13(3):e0194598
37. Singanayagam A, Chalmers JD, Welte T. Epidemiology of CAP in Europe. Eur Respir Monogr. 2014;63:1–12
38. Song J-H, Huh K, Chung DR. Community-acquired pneumonia in the Asia-Pacific region. Semin Respir Crit Care Med. 2016;37:839–854
39. Aston SJ, Rylance J. Community-acquired pneumonia in sub-Saharan Africa. Semin Respir Crit Care Med. 2016;37:855–867
40. Aston SJ. Pneumonia in the developing world: characteristic features and approach to management. Respirology. 2017;22:1276–1287
41. Iannella HA, Luna CM. Community-acquired pneumonia in Latin America. Semin Respir Crit Care Med. 2016;37:868–875
42. Herrero FS, Olivas JB. Microbiology and risk-factors for community-acquired pneumonia. Semin Respir Crit Care Med. 2012;33:220–231
43. Remington LT, Sligl WI. Community-acquired pneumonia. Curr Opin Pulm Med. 2014;20:215–224
44. Marrie TJ, File TM, Jr. Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults. UpToDate. 2018
45. Almirall J, Serra-Prat M, Bolibar I, et al. Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. Respiration. 2017;94(3):299–311
46. Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004
47. Restrepo MI, Mortensen EM, Anzueto A. Common medications that increase the risk for developing community-acquired pneumonia. Curr Opin Infect Dis. 2010;23:145–151
48. Chen T-Y, Winkelman JW, Mao W-C, et al. The use of benzodiazepine receptor agonists and the risk of hospitalization for pneumonia. A nationwide population-based nested case-control study. Chest. 2018;153(1):161–171
49. Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68:1057–1065
50. Muthumbi E, Lowe BS, Muyodi C, et al. Risk factors for community-acquired pneumonia among adults in Kenya: a case-control study. Pneumonia. 2017;9:17
51. Almeida A, Boattini M. Community-acquired pneumonia in HIV-positive patients: an update on etiologies, epidemiology and management. Curr Infect Dis Rep. 2017;19(1):2
52. Torres A, Blasi F, Dartois N, et al. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70:984–989
53. Curcio D, Cané A, Isturiz R. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. Int J Infect Dis. 2015;37:30–35
54. Grau I, Ardanuy C, Calatayud L, et al. Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections. Int J Infect Dis. 2014;25:59–64
55. G.Waterer. Community-acquired pneumonia: a global perspective. Semin Respir Crit Care Med. 2016;37:799–805
56. Cilloniz C, Ewig S, Gabarrus A, et al. Seasonality of pathogens causing community-acquired pneumonia. Respirology. 2017;22(4):778–785
57. Feldman C, Anderson R. The role of Streptococcus pneumoniae in community-acquired pneumonia. Semin Respir Crit Care Med. 2016;37:806–818
58. Cillóniz C, Cardozo C, García-Vidal C. Epidemiology, pathophysiology, and microbiology of community-acquired pneumonia. Ann Res Hosp. 2018;2:1
59. Lung M, Rello J, Microbiology of bacterial CAP using traditional and molecular techniques. Eur Respir Monogr. 2014;63:25–41
60. Gadsby NJ, Russell CS, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis. 2016;62(7):817–823
61. Da Rocha Neto OG, Leite RF, Baldi BG. Update on viral community-acquired pneumonia. Rev Assoc Med Bras. 2013;59(1):78–84
62. Rohde GGU. The role of viruses in CAP. Eur Respir Monogr. 2014;63:74–87
63. Jain S. Epidemiology of viral pneumonia. Clin Chest Med. 2017;38:1–9
64. A.F.Shorr, K.Fisher, S.T.Micek. The burden of viruses in pneumonia associated with acute respiratory failure. Chest. 2018;154(1):84-90
65. Cavallazzi R, Ramirez JA. Influenza and viral pneumonia. Clin Chest Med. 2018;39:703–721
66. Wu X, Wang Q, Wang M, et al. Incidence of respiratory viral infections detected by PCR and real-time PCR in adult patient with community-acquired pneumonia: a meta-analysis. Respiration. 2015;89(4):343–352
67. Burk M, El-Kersh K, Saad M, et al. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev. 2016;25(140):178–188
68. Alimi Y, Lim WS, Lansbury L, et al. Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe. J Clin Virol. 2017;95:26–35
69. Ieven M, Coenen S, Loens K, et al. Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries. Clin Microbiol Infect. 2018;24(11):1158-1163
70. Musher DM, Abers MS, Bartlett JG. Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus. Clin Infect Dis. 2017;65(10):1736–1744
71. Torres A, Blasi F, Peetermans WE, et al. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33:1065–1079
72. Peto L, Nadjm B, Horby P, et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg. 2014;108:326–337
73. Yin JK, Jayasinghe SH, Charles PG, et al. Determining the contribution of Streptococcus pneumoniae to community-acquired pneumonia in Australia. Med J Aust. 2017;207(9):396–400
74. Scott JAG, Hall AJ, Muyodi C, et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet. 2000;355:1225–1230
75. Nyamande K, Lalloo UG, John M. TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence. Int J Tuberc Lung Dis. 2007;11(12):1308–1313
76. Para RA, Fomda BA, Jan RA, et al. Microbial etiology in hospitalized North Indian adults with community-acquired pneumonia. Lung India. 2018;35:108–115
77. Marchello C, Dale AP, Thai TN, et al. Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: a meta-analysis. Ann Fam Med. 2016;14:522–566
78. Arnold FW, Summersgill JT, Ramirez JA. Role of atypical pathogens in the etiology of community-acquired pneumonia. Semin Respir Crit Care Med. 2016;37:819–828
79. Sharma L, Losier A, Tolbert T, et al. Pneumonia updates on Legionella, Chlamydophila, and Mycoplasma pneumonia. Clin Chest Med. 2017;38(1):45–58
80. Arnold FW, Summersgill JT, Lajoei AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175(10):1086–1093
81. Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol. 2016;7:974
82. Yin YD, Wang R, Zhuo C, et al. Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in china: a prospective multicenter surveillance study. J Thorac Dis. 2017;9(10):3774–3781
83. Cao B, Qu JX, Yin YD, et al. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance. Clin Respir J. 2017;11(4):419–429
84. Serota DP, Sexton ME, Kraft CS, et al. Severe community-acquired pneumonia due to Acinetobacter baumannii in North America: case report and review of the literature. Open Forum Infect Dis. 2018;5(3):ofy044
85. Cilloniz C, Martin-Loeches I, Garcia-Vidal C, et al. Microbial etiology of pneumonia: epidemiology, diagnosis and resistance patterns. Int J Mol Sci. 2016;17:2120
86. Ginsburg AS, Tinkham L, Riley K, et al. Antibiotic non-susceptibility among Streptococcus pneumoniae and Haemophilus influenzae isolates identified in African cohorts: a meta-analysis of three decades of published studies. Int J Antimicrob Agents. 2013;42(6):482–491
87. Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis. 2012;205:401–411
88. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455–1463
89. Richter SS, Diekema DJ, Heilmann KP, et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58(11):6484–6489
90. Tomczyk S, Lynfield R, Schaffner W, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016;62(9):1119–1125
91. Shindo Y, Hasegawa Y. Regional differences in antibiotic-resistant pathogens in patients with pneumonia: implications for clinicians. Respirology. 2017;22:1536–1546
92. Torres A, Cillóniz C, Ferrer M, et al. Bacteraemia and antibiotic–resistant pathogens in community acquired pneumonia: risk and prognosis. Eur Respir J. 2015;45(5):1353–1363
93. Naylor NR, Atun R, Zhu N, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. 2018;7:58
94. Fleming V, Buck B, Nix N, et al. Community-acquired pneumonia with risk for drug-resistant pathogens. South Med J. 2013;106(3):209–216
95. Elias C, Moja L, Mertz D, et al. Guideline recommendations and antimicrobial resistance: the need for a change. BMJ Open. 2017;7(7):e016264
96. Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12(2):153–160
97. Gross AE, Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother. 2014;58(9):5262–5268
98. Wunderink RG, Yin Y. Antibiotic resistance in community-acquired pneumonia pathogens. Semin Respir Crit Care Med. 2016;37:829–838
99. Arancibia F, Ruiz M. Risk factors for drug-resistant Cap in immunocompetent patients. Curr Infect Dis Rep. 2017;19:11
100. Schiffner-Rohe J, Witt A, Hemmerling J, et al. Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk–A systematic review and meta-analysis. PLoS One. 2016;11(1):e0146338
101. Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine. 2016;34(13):1540–1550
102. Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12(1):e0169638
103. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014;58(7):909–917
104. Tin Tin Htar M, Stuurman AL, Ferreira G, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017;12(5):e0177985
105. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125
106. Feldman C, Anderson R. Review: current and new generation pneumococcal vaccines. J Infect. 2014;69(4):309–325
107. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043–2051
108. von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014;37(20):1889–1899
109. Lepoutre A, Varon E, Georges S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine. 2015;33(2):359–366
110. Rodrigo C, Bewick T, Sheppard C, et al. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015;45:1632–1641
111. van Werkhoven CH, Hollingsworth RC, Huijts SM, et al. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly. Vaccine. 2016;34(28):3275–3282
112. Pletz MW, Ewig S, Rohde G, et al. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. Vaccine. 2016;34(20):2342–2348
113. Regev-Yochay G, Katzir M, Strahilevitz J, et al. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel. Vaccine. 2017;35(18):2449–2456
114. De Wals P, Lefebvre B, Deceuninck G, et al. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec. Vaccine. 2018;36(3):421–426
115. Tsaban G, Ben-Shimol S. Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: a systematic review of the literature. Vaccine. 2017;35:2882–2891
116. Menéndez R, Espańa PP, Pérez-Trallero E, et al. The burden of PCV13 in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA Study. Vaccine. 2017;35:5264–5270
117. LeBlanc JJ, ElSherif M, Ye L, et al. Burden of vaccine-preventable pneumococcal disease in hospitalized adults: a Canadian immunization research network (CIRN) serious outcomes surveillance (SOS) network study. Vaccine. 2017;35:3647–3654
118. Shiri T, Datta S, Madan J, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet. 2017;5:e51–e59
119. Tin Tin Htar M, Christopoulou D, Schmitt H-J. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15:419
120. Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–543
121. Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18:441–451
122. van der Linden M, Falkenhorst G, Perniciaro S, et al. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One. 2015;10(7):e0131494
123. Katoh S, Suzuki M, Ariyoshi K, et al. Serotype replacement in adult pneumococcal pneumonia after the introduction of seven-valent pneumococcal conjugate vaccines for children in Japan: a systematic literature review and pooled data analysis. Jpn J Infect Dis. 2017;70:495–501
124. Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS One. 2013;10(9):e1001517
125. Puerta-Alcalde P, Cardozo-Espinola C, Cilloniz C, et al. Has mortality of community-acquired pneumonia really reduced? Clin Pulm Med. 2017;24(6):258–262
126. Daniel P, Woodhead M, Welham S, et al. Mortality reduction in adult community-acquired pneumonia in the UK (2009–2014): results from the British thoracic society audit programme. Thorax. 2016;71:1061–1063
127. Ajayi OO, Norton NB, Gress TW, et al. Three decades of follow-up of adults after recovery from invasive pneumococcal pneumonia. Am J Med Sci. 2017;353(5):445–451
128. Wagenvoort GHJ, Sanders EAM, de Melker HE, et al. Long-term mortality after IPD and bacteremic versus non-bacteremic pneumococcal pneumonia. Vaccine. 2017;35:1749–1757
129. Feldman C, Anderson R. Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia pneumonia. Pneumonia (Nathan). 2016;8:11
130. Rae N, Finch S, Chalmers JD. Cardiovascular disease as a complication of community-acquired pneumonia. Curr Opin Pulm Med. 2016;22(3):212–218
131. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125(6):773–781
132. Violi F, Cangemi R, Falcone M, et al. Cardiovascular complications and short-term mortality risk in community-acquired pneumonia. Clin Infect Dis. 2017;64(11):1486–1493
133. Corrales-Medina VF, Taljaard M, Yende S, et al. Intermediate and long-term risk of new-onset heart failure after hospitalization for pneumonia in elderly adults. Am Heart J. 2015;170(2):306–312
134. Cangemi R, Calvieri C, Falcone M, et al. Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascular events. Am J Cardiol. 2015;116(4):647–651
135. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198:962–970
136. Chao CM, Lai CC, Chan KS, et al. Outcomes of patients with severe influenza infection admitted to intensive care units: a retrospective study in a medical centre. J Med Microbiol. 2017;66:1421–1428
137. Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis. 2014;58(2):214–224
138. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017. Available from: https://goldcopd.org
139. Centers for Disease Control and Prevention. Chronic pulmonary obstructive disease among adults - United States 2011. MMWR Morb Mortal Wkly Rep. 2012;61(46):938–942
140. [cited 2018 Jul7]. Available from: http://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
141. Lim S, Lam DC, Muttalif AR, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med. 2015;14:4
142. [cited 2018 Jul 7] Available from: http://www.cia.gov/library/puplications/the-world-factbook/index.html
143. Overbeek JA, Penning-van BFJA, Balp M, et al. Burden of exacerbations in patients with moderate to very severe COPD in the Netherlands: a real-life study. Copd. 2015;12:132–143
144. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138
145. Müllerová H, Shukla A, Hawkins A, et al. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4:e006171
146. Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5:619–626
147. Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183(3):388–395
148. Lambert AA, Kirk GD, Astemborski J, et al. HIV infection is associated with increased risk for acute exacerbation of COPD. J Acquir Immune Defic Syndr. 2015;69(1):68–74
149. Einarsson GG, Comer DM, McIlreavey L, et al. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax. 2016;71:795–803
150. Wang Z, Bafadhel M, Halder K, et al. Lung microbiome dynamics in COPD exacerbations. Eur Resp J. 2016;47:1082–1092
151. Raoult D. The study of microbiota needs both microbiologists and medical doctors. Clin Microbiol Infect. 2017;23:500–501
152. Seemungal T, Harper-Owens E, Rhowmilk A, et al. Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1618–1623
153. Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation in COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2014;9:1101–1110
154. Zwaans WAR, Mallia P, van Winden MEC, et al. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease–a systematic review. J Clin Virol. 2014;61:181–188
155. Buss L, Hurst JR. Viruses and exacerbations of chronic obstructive pulmonary disease: unmet clinical need. J Virus Erad. 2015;1:208–210
156. Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology. 2016;21:1152–1165
157. Wilkinson TMA, Aris E, Bourne S, et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017;72:919–927
158. Sharana H. Aerobic bacteriological study of acute exacerbations of chronic obstructive pulmonary disease. J Clin Diagn Res. 2015;9(8):DC10–DC12
159. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40–46
160. Lode H, Allewelt M, Balk S, et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection. 2007;35:143–149
161. Ferrer M, Ioanas M, Arancibia F, et al. Microbial airway colonization is associated with noninvasive ventilation failure in exacerbation of chronic obstructive pulmonary disease. Crit Care Med. 2005;33:2003–2009
162. Gallago M, Pomares X, Espasa M, et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med. 2014;14:103
163. C.Esteban, S.Garcia-Gutierrezb, M.J.Legarretab. One-year mortality in COPD after an exacerbation: the effect of physical activity changes during the event. COPD. 2016;13:718–725